Oportuzumab monatox (VB4-845) and citatuzumab bogatox (VB6-845) are fusion proteins comprised of an anti-EPCAM single-chain variable fragment (ScFv) or Fab bound to pseudomonas endotoxin A or non-immunogenic toxin of Bougainvillea spectabilis
In non-clinical research literature, this peptide fragment has been referenced in studies exploring angiogenesis markers, fibroblast activity, and collagen expression within controlled laboratory environments
It is about restoring capacity, rebuilding strength, improving mechanics, and safely returning to activity
A typical bacteriostatic water vial contains 30ml, enough for multiple reconstitutions
However, data on oral bioavailability is limited and may vary greatly depending on formulation
How can we ensure that these frameworks and norms align with principles of justice, inclusion, and equity